Category: What’s New in MS Research

Reviewed by MSAA Chief Medical …

Reviewed by MSAA Chief Medical …

It wasn’t just the music that had multiple sclerosis (MS) researchers, clinicians, and advocates in an upbeat mood when they gathered in Nashville from May 29th through June 1st for the Consortium of Multiple Sclerosis Centers’ (CMSC) 2024 Annual Meeting. Rather, the positive vibes reflected the many encouraging developments in MS research reported during the CMSC’s multi-day gathering.

The astounding breadth of research being conducting into the causes, manifestations, and management of multiple sclerosis (MS) was on full display when thousands of physicians, nurses, laboratory scientists, and others gathered in Denver in April for the annual meeting of the American Academy of Neurology (AAN).

From February 29th through March 2nd of this year, MS researchers and clinicians gathered in West Palm Beach for the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024. These healthcare professionals came not only to ask questions but also to provide answers obtained from recent studies addressing varied facets of multiple sclerosis.

The new year began with welcome news on many fronts in terms of clinicians’ enhanced ability to understand and treat multiple sclerosis (MS) and patients’ enhanced ability to improve their health. This edition of “What’s New in MS Research” highlights several of those findings. They include information on a telehealth program that drove significant weight loss in people contending with both MS and obesity, and an internet-delivered cognitive behavioral therapy intervention designed specifically for people with MS that has been shown to reduce depressive symptoms.

Milan, Italy served as the setting for cutting-edge science and high hopes last month, when multiple sclerosis (MS) researchers and clinicians from around the world gathered there in October for MSMilan2023, the 9th joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS).

This edition of “What’s New in MS Research” opens with a pair of “firsts:” the first listing of multiple sclerosis (MS) therapies on the World Health Organization’s List of Essential Medicines and the first United States Food and Drug Administration (FDA) approval of a biosimilar therapy for the long-term treatment of MS.

More than 1,800 multiple sclerosis (MS) researchers, clinicians, and advocates recently convened at the base of the Rocky Mountains for high-level discussions on the latest findings on the potential causes, impact, diagnosis, and management of MS.

Multiple sclerosis (MS) clinicians and research were well represented when neurologists from across the country and around the world gathered in Boston in April for the 75th Annual Meeting of the American Academy of Neurology (AAN). Indeed, findings from more than 270 studies on various aspects of MS were presented at the meeting.